<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00180830</url>
  </required_header>
  <id_info>
    <org_study_id>EGPS-01</org_study_id>
    <secondary_id>CSET-2002/940</secondary_id>
    <secondary_id>CSTI 571BFR10</secondary_id>
    <nct_id>NCT00180830</nct_id>
  </id_info>
  <brief_title>Glivec Phase II Pediatric Study</brief_title>
  <official_title>Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Glivec is effective, in children,&#xD;
      adolescents and young adults, in the treatment of malignant disease in which evidence&#xD;
      suggests a potential pathogenic role of one or more of the tyrosine kinases known to be&#xD;
      inhibited by Glivec.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- Tumour Response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival, overall Survival, safety and tolerability, pharmacokinetic profile and pharmacodynamics of Glivec, pharmacogenetics</measure>
  </secondary_outcome>
  <enrollment>36</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients from 6 months to 21 years of age.&#xD;
&#xD;
          -  Malignant disease documented by conventional criteria to be refractory to standard,&#xD;
             approved therapy, or for which no conventional therapies of definitive benefit exist.&#xD;
&#xD;
          -  Immunohistochemistry documentation of positivity of either Kit (CD117) or PDGF-R in&#xD;
             tumor tissue relevant. Each positive tumor will be centrally reviewed before inclusion&#xD;
             of the patient in the trial.&#xD;
&#xD;
          -  Measurable or evaluable disease.&#xD;
&#xD;
          -  WHO Performance status 0,1, or 2 or Lansky Play Scale &gt;= 50%.&#xD;
&#xD;
          -  Adequate organ function, defined as the following: total bilirubin &lt; 1.5 x ULN, SGOT&#xD;
             and SGPT &lt; 2.5 x UNL (or &lt; 5 x ULN if hepatic disease involvement is present),&#xD;
             creatinine &lt; 1.5 x ULN, ANC &gt; 1x 109/L, platelets &gt; 75 x 109/L.&#xD;
&#xD;
          -  Female patients of child-bearing potential must have negative pregnancy test within 7&#xD;
             days before initiation of study drug dosing.&#xD;
&#xD;
          -  Male and female patients of reproductive potential must agree to employ an effective&#xD;
             barrier method of birth control throughout the study and for up to 3 months following&#xD;
             discontinuation of study drug.&#xD;
&#xD;
          -  Life expectancy of more than 6 weeks.&#xD;
&#xD;
          -  Written, voluntary, informed consent, including consent for retrieval and&#xD;
             investigational use of tissue samples for evaluation signed by parents or young adult&#xD;
             patients.&#xD;
&#xD;
          -  National and, when needed, local ethical approval.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with hematological disease positive for the chimeric BCR-ABL fusion protein or&#xD;
             for c-kit.&#xD;
&#xD;
          -  Patient has received any other investigational agents within 28 days of first day of&#xD;
             study drug dosing.&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Patient has another severe and/or life-threatening medical diseasePatient has an acute&#xD;
             or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis).&#xD;
&#xD;
          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Patient has received chemotherapy within 4 weeks (6 weeks for nitrosourea, mitomycin-C&#xD;
             or any antibody therapy) prior to study entry unless urgent enrollment needed and&#xD;
             approved by the study coordinator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Vassal, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Morland</last_name>
    <role>Study Chair</role>
    <affiliation>Birmingham Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave-Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emma Kinderziekenhuis AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2006</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

